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Case Report
Abstract
Sebaceous gland carcinoma is a rare fast growing cutaneous cancer. It is derived from the adenxal epithelium of sebaceous
glands. Sebaceous carcinomas are generally divided into those occurring in periocular or extraocular locations. Ocular sebaceous
carcinomas occur most commonly in upper eye lid, in the elderly with a predilection for females and Asian populations. Due to
its clinical resemblance with chalazion or other chronic inflammatory conditions, there is a delay in diagnosis. Due to its rarity,
we present a case of sebaceous carcinoma of right upper eyelid in a 65-year-old female.
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Introduction
Sebaceous carcinoma was first reported by Allaire in 1891.
Its incidence is less than 1% of all skin malignancies. Seba-
ceous carcinoma is the fourth most common neoplasms of
the eyelid and arises mainly from the meibomian or less
commonly from Zeis glands. It is a rare but fast growing
malignant neoplasm with a tendency for both local recur-
rence and distant metastases. Sebaceous carcinoma can either
be ocular or extraocular, and extraocular type is rare.1 Ad-
vanced age, Asian or South Asian race, women, previous
irradiation to the head and neck, a genetic predisposition for
Muir-Torre syndrome or possibly familial retinoblastoma are
various predisposing factors for sebaceous carcinoma. It
mostly spread to regional lymph nodes. It may invade orbit,
and 22% of patients die due to visceral metastases.2
Case History
A 65-year-old female patient presented with a mass over
right upper eyelid (Figure 1). Patient complained of de-
creased vision & foreign body sensation in the right eye for 6
months prior to reporting the case. Fine needle aspiration
cytology (FNAC) was performed using standard technique.
Staining was done with papanicolaou stain & May Grunwald
Giemsa (MGG) stain. Smears demonstrated tumor cells ar-
ranged in irregular clusters and as single cells. The cells con-
tain moderate amount of finely reticular cytoplasm with
various degrees of vacuolization. Pleomorphic centrally lo-
cated nuclei containing coarse chromatin & prominent nu-
cleoli were seen (Figure 2).
FIG. 1 (left): Patient Photo showing swelling right upper eyelid.
FIG. 2 (right): Cytological smear showing sebaceous carcinoma MGG
(high power).
Tumor was excised and Oil red O staining of fresh frozen
tissue was done for confirmation of sebaceous carcinoma.
Histopathology revealed irregular epithelial lobules with
atypical dark pleomorphic cells with abundant foamy, finely
vacuolated cytoplasm & well defined borders. The tumor
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cells manifested marked pleomorphism, prominent nucleoli
& numerous mitotic figures (Figures 3 and 4). CAM 5.2
staining was done to differentiate between the normal &
malignant sebaceous lesions. CAM 5.2 staining was strongly
positive for sebaceous carcinoma.
FIG. 3: Histopathology salide showing sebaceous carcinoma H&E
under low power.
FIG. 4: Histopathology salide showing sebaceous carcinoma H&E
under high power.
Discussion
Sebaceous carcinoma is a rare and destructive malignant
neoplasm. It frequently occurs in adults with a female pre-
dominance.3 This malignancy can occur as periocular and
extraocular regions and the former type is about 75% of se-
baceous neoplasms. Upper eyelid is affected two to three
times more often than the lower eyelid due to high number
of meibomian glands.4 According to literature, ocular seba-
ceous carcinoma arose from the meibomian glands in 51 to
70% of cases; multicentric in origin in 12 to 24 %; and 4 to
10% arose from the glands of Zeiss; the few originated from
the caruncle or orbit. Incidence of extraocular sebaceous
carcinoma is about 25% of the sebaceous neoplasms and
mostly effects the head and neck areas followed by trunk,
salivary glands, genitalia, breast, ear canal, and the intra-oral
cavity.3
The clinical presentation of ocular sebaceous carcinoma is
varied and an accurate diagnosis is delayed for months to
years. The mean delay from onset of disease to diagnosis is
about 1 to 2.9 years. The most common clinical presentation
is a small, erythematous or possibly yellowish, slowly en-
larging, firm, deep seated papule or nodule on the upper
eyelid. It may resemble with a chalazion, keratoconjunctivits
or blepharoconjunctivitis. Numerous other inflammatory
conditions, autoimmune diseases, infectious processes, and
basal cell carcinoma may clinically imitate sebaceous carci-
noma of the eyelid. Due to variable clinical presentations of
ocular sebaceous carcinoma, a high degree of suspicion and
ultimate biopsy of non-healing lesions is critical in making
the final diagnosis. Sometime diagnosis is made only after
metastases to the regional lymph node or parotid gland.5
TABLE 1: Classification of sebaceous carcinoma based on degree of
differentiation by Font6 (top) and Wolfe et al.7 (bottom)
Classification by Font.6
Well Differentiated Contains many neoplastic cells ex-
hibiting sebaceous differentiation
with abundant finely vacuolated
cytoplasm. Areas of sebaceous dif-
ferentiation are often toward the
center of tumor lobules
Moderately Differentiated Only a few areas of highly differen-
tiated sebaceous cell are seen. The
majority of the tumor is composed of
neoplastic cells with hyperchromatic
nuclei and prominent nucleoli and
abundant basophilic cytoplasm
Poorly Differentiated The majority of cells exhibit pleo-
morphic nuclei with prominent
nucleoli and scant cytoplasm. A
moderate increase in mitotic activity
is present.
Classification by Wolfe et al.7
Grade I Well differentiated; foamy cytoplasm present in all
cells.
Grade II Large vacuolated nuclei and foamy cytoplasm seen in
most cells
Grade III Small hyperchromatic nuclei and little cytoplasm
present in most cells
Grade IV Undifferentiated; small hyperchromatic nuclei and
little cytoplasm; diagnosis requires positive fat stain,
ultrastuctural study or areas of better differentiation.
Histologically, sebaceous carcinoma has to be differentiated
from basal cell carcinoma, squamous cell carcinoma,
trichilemmal keratinisation, sebaceous adenoma and seba-
ceous epithelioma. Special stains such as oil red O may be
helpful in confirming the presence of fat, but requires frozen
section. Immunohistochemical studies may also be employed
to confirm the diagnosis. Sebaceous carcinoma cells express
immunohistochemical markers such as cytokeratin, epitheli-
al membrane antigen (EMA), Cam5.2 and anti-breast carci-
noma associated antigen-225 antibody. The cause of sporadic
sebaceous carcinomas is still unclear. Previous radiation to
the area is a well-documented risk factor, especially in chil-
dren.8 Sebaceous carcinoma may be associated with use of
oral diuretic like thiazide. The diuretic causes production of
carcinogenic nitrosamines which may play a role in the car-
cinogenesis of the sebaceous carcinomas in these patients.9
However, there is no firm etiologic link between diuretic use
and the development of sebaceous carcinoma.
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The molecular mechanisms for tumor development and pro-
gression are recently being studied. It has been assumed that
the loss of p53 and the consequent disruption of genomic
integrity might play a critical role in the progression of se-
baceous carcinoma.10 Ocular sebaceous carcinoma may me-
tastasize via the lymphatics, the blood vessels, by the lacri-
mal secretory system, and the lacrimal excretory system.
Metastases occur in approximately 8 to 25% of patients, and
metastasize to regional lymph nodes, followed by involve-
ment of the liver, lungs, brain, and bones. Lymphatic metas-
tases involve preauricular, submandibular, or cervical lymph
nodes, with or without secondary parotid masses. Distant
metastases and recurrence rates are more common in the
ocular type of sebaceous carcinoma.11 Recurrence rates of
ocular sebaceous carcinoma ranges from 11% to 30% with
distant metastases occurring in 3% to 25% .11 In sebaceous
carcinoma of eye lid, there is local loss of the eyelashes due
to tumour infiltration of the follicle.  If tumor is one sided
and every therapy is ineffective then there are more chances
of sebaceous carcinoma. A full thickness eyelid biopsy com-
bined with conjunctival map biopsies is necessary for the
diagnosis.12 Once a diagnosis of sebaceous carcinoma is con-
sidered, a detailed history and physical examination should
be done. Colonoscopy and barium enema are essential to rule
out internal malignancies associated with the Muir-Torre
syndrome.
The primary treatment of sebaceous carcinoma is complete
surgical excision. Mohs micrographic surgery is most com-
monly done.13 Excision of tumor with frozen section is man-
datory for proper management. Conjunctival map biopsies
should be done at the time of surgery to assess for potential
pagetoid spread. Microscopically it tends to extend far be-
yond its assessed clinical margins as it may spread by direct
extension, be multifocal in advanced cases, and may develop
"skip areas" after injury. Despite its ability to develop “skip
areas”, Mohs micrographic surgery (MMS) is a ideal mode of
treatment.14 Subtotal or complete exenteration is required if
the tumour is very large or recurrent with spread to bulbar
conjunctiva, to the other eyelid, or to orbital tissue. Radical
neck dissection along with partial parotidectomy is per-
formed If it spread to regional lymph nodes.12
The missing tarsoconjunctival structures and skin should be
reconstructed properly to protect the eye globe and should
give a natural appearance with only minor deficiency. Ideal-
ly it should be one stage procedure. The vascularised tem-
poral island flap can be used as one stage procedure. As it is
fast growing cancer, postoperative patient should be fol-
lowed up at 3 monthly interval during the first year, 6
monthly during the second year, and then on a yearly basis
for life.12 Cryotherapy can be utilized as adjunctive therapy
to treat patients with residual conjunctival intraepithelial
disease or in those patients in whom definitive surgical exci-
sion is not possible. Topical mitomycin C has also been used
as an adjunctive therapy in patients with intraepithelial in-
volvement.15 Sebaceous carcinoma is relatively radio re-
sistant, so, radiotherapy may be used as palliative therapy for
inoperable patients.13 Total dose of radiation is about >50 Gy.
If radiation alone is used then tumor may reoccur within 3
years.
Finally, metastatic disease may be treated with a combina-
tion of excision, radiation, and chemotherapy. A schedule of
intralesional 5-flurouracil in combination with intravenous
5-fluorouracil, doxorubicin, cisplatin, and vinblastine has
been used.16 Mortality rates irrespective of ocular or extraoc-
ular type ranges from 9% to 50%.17
Conclusion
Sebaceous carcinoma is a fast growing tumor and it is mostly
seen on the eyelid. Since it clinically resembles other diseases,
it presents challenge in diagnosis. Early, precise and prompt
diagnosis is vital as it spreads out regionally as well to other
distant organs. It may be associated with Muirre- Torre syn-
drome. The inconsistent appearance mostly causes delay in
diagnosis, improper treatment, increased morbidity, and
mortality.
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